oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 713 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Ibuprofen B. Braun – recalled product

Ibuprofen B. Braun

CRITICAL 04.08.2023

Cross-contamination of infusion solutions in the listed batches of B. Braun medicinal products was detected and reported via the Rapid Alert system by the German pharmaceutical authority. Potential effects: possible severe adverse reactions, poisoning, lack of therapeutic efficacy or infusion-related complications.

Ibuprofen B. Braun – recalled product

Ibuprofen B. Braun

CRITICAL 04.08.2023

Cross-contamination of infusion solutions was found in the listed batches of B. Braun medicinal products, reported via the Rapid Alert system by the Hessisches Landesamt für Gesundheit und Pflege as potentially endangering the safety of intravenous therapy. Potential effects: poisoning, severe adverse reactions, lack of efficacy, treatment complications.

Fluconazole B. Braun 2 mg/ml – recalled product

Fluconazole B. Braun 2 mg/ml

CRITICAL 04.08.2023

Cross‑contamination of infusion solutions was detected in the above-mentioned medicinal product batches, which may lead to administration of an incorrect substance or dose to the patient. Potential effects: poisoning, serious adverse reactions, allergic reactions, lack of efficacy, severe systemic complications.

Paracetamol B. Braun – recalled product

Paracetamol B. Braun

CRITICAL 04.08.2023

detection of cross-contamination of infusion solutions in the above-mentioned series of medicinal products Potential effects: poisoning, unpredictable adverse reactions, lack of therapeutic efficacy, perioperative complications.

Lactulose-MIP – recalled product

Lactulose-MIP

MEDIUM 01.08.2023

A deviation in the manufacturing process was identified; deterioration of product quality during the shelf life cannot be excluded, thus creating a risk to patient health. Potential effects: lack of therapeutic efficacy or adverse reactions.

Lactulose-MIP – recalled product

Lactulose-MIP

MEDIUM 01.08.2023

Deviations were identified in the product manufacturing process, so deterioration of its quality during the shelf life cannot be excluded, and therefore there is a potential risk to patient health. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.

Sabril – recalled product

Sabril

CRITICAL 31.07.2023

Due to the detected presence of tiapride, a risk to the patient’s health or life cannot be excluded; the presence of trace amounts of tiapride may theoretically result in numerous serious and life‑threatening adverse reactions. Potential effects: severe, potentially life‑threatening adverse reactions.

Sabril – recalled product

Sabril

CRITICAL 31.07.2023

The presence of tiapride above 0.3 ppm in vigabatrin products may theoretically lead to numerous serious and life‑threatening adverse reactions; a risk to the patient’s health or life cannot be excluded. Potential effects: serious adverse reactions, including life‑threatening events.

Pasta borowinowa lecznicza – recalled product

Pasta borowinowa lecznicza

CRITICAL 28.07.2023

An excessive amount of Clostridium perfringens and the presence of Candida farmata/guilliermondii yeasts were detected, meaning the product does not meet microbiological purity requirements and may pose a health risk to patients when applied to the skin. Potential effects: skin infections, irritation, complications in immunocompromised individuals.

Tresuvi – recalled product

Tresuvi

CRITICAL 24.07.2023

Unidentified solid particles were detected in the solution for infusion; due to the unknown nature of the contamination, a risk to patients’ health and life cannot be excluded. Potential effects: thrombotic complications, emboli, inflammatory reactions, life-threatening events.

Andepin – recalled product

Andepin

MEDIUM 24.07.2023

Due to the detected increased content of a single impurity, a health risk for the patient taking this product cannot be excluded. Potential effects: poisoning, increased adverse reactions, complications of therapy.

Autostrzykawka Morfina Przeciwko Bólowi – recalled product

Autostrzykawka Morfina Przeciwko Bólowi

CRITICAL 18.07.2023

Due to the detected solution discoloration that does not comply with quality requirements, the risk to the patient’s health and life cannot be excluded. Potential effects: poisoning, severe adverse reactions, life-threatening complications.

Sirdalud MR – recalled product

Sirdalud MR

HIGH 07.07.2023

It is not possible to guarantee specification-compliant active substance release after 2 hours until the end of the shelf-life, which may affect the quality and safety of product use. Potential effects: lack of treatment efficacy or increased adverse effects.

Sirdalud MR – recalled product

Sirdalud MR

MEDIUM 07.07.2023

It is not possible to guarantee specification-compliant release of tizanidine hydrochloride after 2 hours, and the cause is not fully understood, so the impact on product quality and safety of use cannot be predicted. Potential effects: lack of treatment efficacy or adverse effects related to incorrect dosing.

Detimedac 200 mg – recalled product

Detimedac 200 mg

CRITICAL 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, complications of oncological therapy, possible adverse effects related to degradation products.

Detimedac 500 mg – recalled product

Detimedac 500 mg

CRITICAL 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, possible adverse reactions.

Detimedac 100 mg – recalled product

Detimedac 100 mg

CRITICAL 03.07.2023

Pink discoloration may be caused by degradation of the active substance, which may represent an increased risk to the patient. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.

Lorabex – recalled product

Lorabex

CRITICAL 29.06.2023

It was suspected that the product might not meet quality requirements (out-of-specification results for lorazepam content and related substances), but testing of samples taken from the market confirmed correct quality of the batch. Potential effects: possible alteration of drug action, lack of efficacy or adverse effects.

Mebelin – recalled product

Mebelin

MEDIUM 26.06.2023

Due to the reduced values of active substance release in the product, the risk to patient health resulting from decreased drug efficacy cannot be excluded. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.

PALIFREN LONG – recalled product

PALIFREN LONG

MEDIUM 16.06.2023

A reduced content of the active substance paliperidone palmitate and an increased particle size compared to requirements were found, which may lead to reduced medicinal efficacy and a risk to patient health. Potential effects: reduced treatment efficacy, worsening of disease symptoms.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.